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Type 2 diabetes mellitus (T2DM) has become a global pandemic. It is now estimated
that nearly 387 million people have diabetes globally.1 Rates in developing countries are
increasing due to the changes in rates of obesity and inactivity. Deaths from diabetes are
projected to increase 50% worldwide by 2025. Eighty percent of these deaths will occur
in low and middle income countries.2 T2DM is a complex and progressive disease. Once
thought of as only a disease of insulin resistance, it is now believed that there are at least
eight pathologic processes that lead to type 2 diabetes.3 These include abnormal β-cell
insulin secretion, excessive α-cell glucagon production, abnormal incretin effect, insulin
resistance at the peripheral tissues, increased hepatic glucose production, increased
lipolysis, neurotransmitter dysfunction, and abnormal renal handling of hyperglycemia.3
Knowledge of these pathophysiologic mechanisms is critical in the development and
use of targeted treatments that have complementary mechanisms of action.
Insulin resistance is usually maximal at the time a person is diagnosed with T2DM.
β-cell dysfunction and failure become prominent defects in this progressive disease.
As T2DM is a multisystemic and progressive disease, no single therapy is adequate
for long-term control. Treatment must be multifactorial, and combination therapy is
often necessary. Most of the current available treatments are insulin “centric”, meaning that they need insulin production to provide therapeutic benefit. These therapies
only have a therapeutic effect as long as there is measurable insulin production. One
of the newly discovered pathophysiologic processes that can be treated is increased
renal glucose reabsorption that occurs in diabetes.4 This treatment is novel because
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Abstract: In the last decade, researchers have gained a greater understanding of the
pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of
the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes
by increasing the reabsorption of glucose above the normal physiologic renal threshold. This
discovery has led to the development of the sodium/glucose cotransporter 2 inhibitors (SGLT2).
These agents readjust the renal threshold for glucose reabsorption to a lower level and decrease
glucose reabsorption, while increasing urinary glucose when the glucose is above the renal
threshold and subsequently lowering plasma glucose. The mechanism of action of the SGLT2
inhibitors is insulin independent, which makes them a novel treatment of diabetes. At the time
of preparation of this manuscript, there were three SGLT2 inhibitors available in the US. This
manuscript focuses on empagliflozin, the newest SGLT2 inhibitor, the trials in its development,
and the clinical data available to date. Further, the authors propose future applications of empagliflozin, including in the treatment of type 1 diabetes, and its potential role in renoprotection.
Keywords: SGLT-2 inhibitors, empagliflozin, type 2 diabetes, kidneys, type 1 diabetes,
glucosuria
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the kidney has not been a therapeutic target previously, and
the mechanism of action is independent of insulin.
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Introduction to renal glucose
physiology
Plasma glucose is usually maintained in a relatively narrow
range between 70 and 160 mg/dL (3.9 and 8.9 mmol/L).
This involves a delicate balance between glucose production
(liver and kidney), intestinal absorption, renal reabsorption, and glucose utilization in tissues around the body.
In a normal healthy adult, kidneys can filter 160–180 g of
glucose/d (mean glucose 100 mg/dL ×180 L/d).5,6 In euglycemic people, essentially all the filtered glucose is reabsorbed
in the proximal convoluted tubule allowing the glucose to
remain in circulation. The normal filtered glucose load in a
person without diabetes is approximately 125 mg/min, but
can rise when the ambient glucose rises or if the glomerular
filtration rate increases. The maximum renal threshold for
glucose reabsorption occurs when the serum glucose is
approximately 180–200 mg/dL. In these individuals, when
the glucose exposure to the kidney exceeds 200 mg/dL
(11.0 mmol/L), no additional glucose is reabsorbed and the
excessive glucose is excreted in the urine.6
Glucose reabsorption is mediated by the sodium/glucose
cotransporter (SGLT) proteins. This process is independent of
insulin.7 The great majority of the filtered glucose (90%) is reabsorbed in the first segment of the proximal convoluted tubule by
SGLT2. SGLT2 is a low affinity but high capacity transporter.8
The remaining filtered glucose (10%) is removed from the filtrate by SGLT1 in the distal aspect of the proximal convoluted
tubule. SGLT1 is a high-affinity and low-capacity transporter.8
This mechanism allows for conservation of calories.
There are a number of SGLT proteins expressed throughout the body.8 SGLT1 is expressed in the small intestine and
helps to regulate glucose and galactose absorption in the
kidney as mentioned before. People who do not have functioning SGLT1 will suffer from significant gastrointestinal
(GI) complications including severe diarrhea, while those
without functioning SGLT2 appear to live normal lives
despite increased glucosuria. The SGLT2 inhibitors work on
the SGLT1 and SGLT2 proteins. Therefore, high selectivity
toward SGLT2 may be pharmacologically beneficial. Dual
blockade may provide an even greater therapeutic effect,
but it will need to be balanced with the GI effects of SGLT1
blockade (Figure 1).

Renal physiology in type 2 diabetes
People with T2DM routinely experience both fasting and
postprandial hyperglycemia, which is a result of a number of
5794
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maladaptive physiological responses that include exaggerated
hepatic and renal glucose production, impaired insulin secretion, and inefficient glucose uptake.3 Recently, the kidney’s
maladaptive response to chronic hyperglycemia has become
a treatment target in diabetes.
Normal renal physiology dictates that all filtered glucose
is reabsorbed. However, if the plasma glucose levels rise
above 200 mg/dL (11 mmol/L) as seen in diabetes, some
glucose is excreted in the urine. As shown in diabetic mice,
there is upregulation of SGLT2. This might contribute to
the increased plasma glucose threshold before any glucose
is seen in the urine.9
However, in mouse models of diabetes mellitus, there
is upregulation of SGLT2 in response to chronic hyperglycemia, allowing more glucose reabsorption.10 Furthermore,
there is also an increase in SGLT protein expression in diabetes.11 These combine to potentially increase the maximum
renal glucose threshold which contributes to more glucose
reabsorption, which maintains plasma hyperglycemia
(Figure 2).

Early attempts to address abnormal
renal physiology via SGLT proteins
More than 100 years ago, it was identified that a botanical
agent could induce glucosuria. The active ingredient was later
identified as phlorizin, a substance found in the bark of apple
trees.12,13 Unfortunately, phlorizin had a number of significant
limitations that made it unviable as a pharmacologic treatment. It had little selectivity for SGLT2 over SGLT1. The
SGLT1 activity resulted in significant GI side effects. Further,
phlorizin has an O-glucosidase which makes it susceptible
to degradation by the β-glucosidase in the intestine, so it
required IV dosing.14
Empagliflozin is structurally similar to phlorizin but
with some important differences. It has a C-glucoside
with a carbon–carbon bond between the glucose and
aglycone moiety. This makes it resistant to degradation
in the GI tract, allowing it to be orally administered.15
Further, because empagliflozin (EMPA) is highly selective for SGLT2 (2,500-fold), it is less likely to have GI
side effects.7
The glucosuric effects of SGLT2 blockade raised early
concerns about the safety of chronic high glucose levels in
the renal tubules and in the urine. In familial renal glucosuria, people have nonfunctioning SGLT2 proteins from a
mutation of the SLC5A2 gene that encodes SGLT2. These
patients have chronic glucosuria even in the face of normoglycemia. Individuals with this condition rarely suffer
from glucose-related problems and have no known renal
Drug Design, Development and Therapy 2015:9
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Figure 1 Physiology of glucose reabsorption in the proximal convoluted tubule.
Note: Reproduced from Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res.
2015;12(2):78–89,6 copyright ©2015 by (SAGE Publications). Reprinted by Permission of SAGE Publications, Ltd.
Abbreviations: GLUT, glucose transporter; PT, proximal tubule; KCNE1, potassium voltage-gated channel Isk-related family member 1; KCNQ1, potassium voltage-gated
channel KQT-like subfamily member 1; SGLT, sodium-dependent glucose transporter.

tubular dysfunction and typically do not report increased
genitourinary infections.16
Conversely, loss of function of SGLT1 from a mutation
of SLC5A1 results in little to no glucosuria but significant GI
symptoms because of the glucose–galactose malabsorption
that results in watery diarrhea and potentially dehydration.17
Thus, preferential targeting SGLT2 proteins (rather than
SGLT1) with pharmacologic intervention is preferable.

SGLT2 inhibitors
The SGLT2 inhibitors are a new drug class that address
hyperglycemia by reducing renal glucose reabsorption,
increasing urinary glucose excretion, and consequentially
reducing serum glucose levels.18,19 The SGLT2 inhibitors
work independent of insulin (both secretion and sensitivity),
which makes this class novel and potentially complementary
to most current diabetes therapies.
There are currently three SGLT2 inhibitors available in
the US. Canagliflozin was approved by the US Food and
Drug Design, Development and Therapy 2015:9

Drug Administration (FDA) in March 2013 (FDA news
release 2013),20 dapagliflozin in January 2014, and EMPA
in August of 2014.21 All of these agents are potent competitive inhibitors of the SGLT2 protein, but dapagliflozin and
EMPA are highly selective for SGLT2, while canagliflozin
has dual blockade of SGLT1 and SGLT2. Of the three commercially available SGLT2 inhibitors, EMPA has the highest
selectivity for SGLT2 (2,500-fold) compared to SGLT1.22
The chemical structure for EMPA is shown in Figure 3.

Preclinical studies
Preclinical studies showed that EMPA is a competitive
inhibitor of the SGLT2, has high specificity to SGLT2, and
has a half-life of approximately 60 minutes. Early cell line
studies demonstrated that EMPA is a potent inhibitor of
SGLT2 and has 2,500-fold sensitivity for inhibition of
SGLT2 vs SGLT1.23 Subsequent rodent studies showed that
EMPA reduced blood glucose in a dose-dependent manner
by increasing urinary glucose excretion.22 In one 5-week
submit your manuscript | www.dovepress.com
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Figure 2 Downstream renal effects of SGLT1 and SGLT2 inhibition.
Note: Reproduced from Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res.
2015;12(2):78–89,6 copyright ©2015 by (SAGE Publications). Reprinted by Permission of SAGE Publications, Ltd.
Abbreviations: GLUT, glucose transporter; SGLT, sodium glucose transporter; PT, proximal tubule; LOH, loop of Henle; DT, distal tubule; CD, collecting duct; NHE3,
sodium hydrogen exchanger-3; EGP, endogenous glucose production; SNGFR, single nephron glomerular filtration rate; TGF, tubuloglomerular feedback.

trial, EMPA reduced HbA1c levels by 0.3% (1 mg/kg) and
1.1% (3 mg/kg).24

Human Phase I studies
A single dose of EMPA was studied in 72 healthy males.25
Subjects were randomized to placebo or a dose of EMPA
between 0.5 and 800 mg. EMPA was quickly absorbed
with a maximum plasma concentration at approximately
1.5–2.1 hours, with drug exposure proportional to the dose
administered. EMPA had a biphasic decline in concentration in the decay phase, with a terminal half-life from
8.6–13.1 hours.22 In these studies, the urinary glucose excretion increased to a maximum at the 50 mg dose, significantly
higher than placebo.25 Food and postprandial state had no
effect on drug absorption, and glucosuria was similar after
meals in these healthy subjects. All side effects were similar
to placebo (headaches, GI, and nervous system disorders)
and were not dose dependent. One hypoglycemic event was
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reported (glucose 53 mg/dL [2.9 mmol/L]) during a 3-hour
glucose tolerance test.
Another series of Phase I trials tested EMPA 1–100 mg
in 48 healthy Japanese men.26 In these studies, EMPA was
rapidly absorbed with a maximum concentration at around
1.25–2.5 hours, with drug exposure and clearance relative to
the dose administered. EMPA exposure was approximately
1.5 times higher in this study possibly due to differences in
body weight between the population studies. The urinary
glucose clearance was dose dependent as well. EMPA was
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Figure 3 Chemical structure of empagliflozin (Jardiance®).
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well tolerated (mild side effects, not dose dependent), and
no hypoglycemia was reported.
Finally, the pharmacokinetic (PK) and pharmacodynamics (PDs) profiles of EMPA were determined after the first
dose on day 1 and at steady state dosing on day 28. EMPA
was rapidly absorbed with peak concentration at 1.5 hours.
Clearance was biphasic with a range of 13.2–16.5 hours.
Oral clearance showed linear PKs in terms of time.
Eighteen percent of the medication was excreted in the
urine unchanged. The urinary glucose excretion was dose
dependent. Compared to baseline, urinary glucose excretion increased to 74 g in the 10 mg dose, 90 g in the 25 mg
dose, and 81 g in the 100 mg dose. There was essentially no
change in urinary glucose excretion in the placebo group.
Urinary glucose excretion remained constant throughout the
study. No significant changes in urine volume were reported.
There were significant reductions in fasting and post oral
glucose tolerance test glucose readings on day 28 compared
to placebo. A nonsignificant reduction in HbA1c was seen in
the EMPA groups at 28 days (Table 1).27,28

A study evaluated the safety, tolerability, and PK/PD in 78
people with type 2 diabetes.27 Subjects were randomized to
EMPA (10, 25, 100 mg) or placebo. Weighted randomization
was completed for the 100 mg dose (2× other groups) to assess
the safety of this dose. The plasma concentration and urinary
glucose excretion were dose dependent. Urinary glucose
excretion remained elevated throughout the trial compared
to no increase in the placebo-treated group. Side effects were
similar in the treatment arms, with the most common adverse
effects being pollakiuria (10.3%), nasopharyngitis (9.0%),
constipation (9.0%), and headache (7.7%). Urinary-related
adverse effects were more common in the EMPA groups.

In another study, investigators randomized 408 treatment
naïve (or 4-week washout) subjects with type 2 diabetes to
EMPA 25 mg, metformin, or placebo. The overall mean A1c
was 7.9%±0.8% at entry. All EMPA doses had significant
A1c reductions compared to placebo (placebo +0.1%; EMPA
5 mg, -0.4%; 10 mg, -0.5%; 25 mg, -0.6%; all P0.0001)
and showed similar reduction as compared with metformin
(-0.7%).29
A trial evaluated the PK/PD of a single dose of 50 mg of
EMPA in 40 patients with various levels of renal impairment.
The peak concentration was similar to previous studies, but
the total plasma exposure and maximum concentration were
slightly elevated in those with advanced renal impairment.
In this study, the greater the renal impairment, the lower the
urinary glucose excretion.30
There was some initial concern about hepatic safety in
early studies with dapagliflozin. In a similar set of studies
with EMPA (as already mentioned), there did not appear to
be any dose adjustment needed in people with mild, moderate, or severe hepatic impairment.31 These studies are summarized in Table 2.
Some small studies have reported an increase in endo
genous glucose production with SGLT2 inhibitors including
EMPA.32–34 The elevated hepatic glucose production appears
to be a compensatory response to support normal plasma
glucose levels in the presence of sustained urinary glucose
excretion. The plasma glucagon/insulin ratio is a regulator
of hepatic glucose production and so the increase in glucagon could explain the rise in hepatic glucose production
observed with SGLT2 inhibition.33 Overall, glucose levels
are still decreased despite the increase in glucose production.
Further investigation is needed to determine the long-term
significance of this physiologic response and optimal therapeutic approach.

Table 1 Summary of key pharmacokinetic parameters of empag
liflozin 10 and 25 mg at steady state after oral dosing

Clinical benefits of empagliflozin in Phase
III trials

Phase II trials

Pharmacokinetic
parameters

Empagliflozin dose
10 mg qd (n=8)

25 mg qd (n=9)

AUC0–t, ss (nmol h/L)
Cmax, ss (nmol h/L)
tmax, ss (h)a
t1/2, ss (h)
Fe0–24, ss (%)
CLR, t, ss (mL/min)

2,030 (362)
283 (90.1)
1.5 (1.0–2.0)
14.3 (2.4)
18.7 (4.5)
34.4 (7.9)

4,990 (1,080)
630 (106)
2.0 (0.7–4.2)
10.7 (2.1)
12.7 (6.4)
23.5 (8.7)

Notes: Data are mean (SD) unless otherwise indicated. aMedian (range) is denoted.
Reproduced from McGill J. The SGLT2 inhibitor empagliflozin for the treatment of
type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63.57
Abbreviations: AUC, area under concentration–time curve; Cmax, maximum plasma
concentration; CLR, renal clearance; Fe, fraction of dose that was excreted unchanged
in urine; qd, once daily; SD, standard deviation; ss, steady state; t, dosing interval;
t1/2, terminal half-life in plasma; tmax, time to maximum plasma concentration.

Drug Design, Development and Therapy 2015:9

Empagliflozin has been studied as a monotherapy and in
combination therapy for type 2 diabetes. A1c reduction with
EMPA 10 mg (-0.66%) or 25 mg (-0.78%) was statistically
superior to that observed with placebo (0.08%) when given
as monotherapy.35 A1c reduction with EMPA 10 and 25
mg was similar to A1c reduction with sitagliptin 100 mg.35
In this study, body weight decreased significantly with
EMPA 10 mg (-2.26 kg) and 25 mg (-2.46 kg) compared
to placebo (-0.33 kg). Finally, systolic blood pressure
(SBP) decreased significantly with EMPA 10 mg (-2.9
mmHg) and 25 mg (-3.7 mmHg) compared to placebo
(-0.3 mmHg).
submit your manuscript | www.dovepress.com
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Table 2 Empagliflozin pharmacokinetics after administration of a single 50 mg dose in patients with renal or hepatic impairment
Impairment severity
Renal impairment study
Mild (n=9)
Moderate (n=7)
Severe (n=8)
Failure/ESRD (n=8)
Hepatic impairment study30
Mild (n=8)
Moderate (n=8)
Severe (n=8)

Total plasma exposure AUC0–∞ (nmol h/L)

Cmax, ss (nmol/L)

118.2% (96.2, 145.4)
119.9% (96.3, 149.5)
166.3% (134.4, 205.7)
148.3% (119.9, 183.4)

118.8% (93.6, 150.8)
102.3% (79.3, 131.9)
120.7% (94.4, 154.3)
103.8% (81.2, 132.6)

123.15% (98.9, 153.4)
146.97% (118.0, 183.0)
174.70% (140.3, 217.6)

103.8% (82.3, 131.0)
123.3% (97.7, 155.6)
148.4% (117.7, 187.2)
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57

Notes: For both studies, values are adjusted GMR (impaired/normal group), with 90% CI for adjusted GMR. Reproduced from McGill J. The SGLT2 inhibitor empagliflozin
for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63.57
Abbreviations: AUC, area under the concentration–time curve; CI, confidence interval; Cmax, ss, maximum plasma concentration at steady state; ESRD, end-stage renal
disease; GMR, geometric mean ratio.

Nearly two-thirds of the subjects in this study entered
the extension phase of the study for an additional 52 weeks
for a total of 76 weeks. The placebo-subtracted A1c reductions at 76 weeks were 0.78% for EMPA 10 mg, 0.89% for
EMPA 25 mg, with persistent weight loss of 1.8 kg with
10 mg of EMPA and 2.0 kg for 25 mg of EMPA and SBP
reductions of 3.4 mmHg in both the 10 and 25 mg arms
of EMPA.36
As add-on therapy to metformin, EMPA 25 mg has been
shown to be statistically superior to glimepiride in a 104-week
study.37 The A1c reduction was 0.66% with EMPA and 0.55%
with glimepiride. Weight and blood pressure were reduced
with EMPA (-3.1 kg, -3.1 mmHg), and these changes were
not seen with glimepiride (+1.3 kg, +2.1 mmHg).
When EMPA was given in combination with other
medications, there were significant improvements in HbA1c.
Table 3 provides an overview of EMPA with metformin38,39
metformin plus a sulfonylurea,38 pioglitazone or pioglitazone plus metformin,40 or multidose insulin with or without
metformin.41
Statistically significant reductions in body weight
and SBP (relative to placebo) were also found in EMPA
combination studies. These studies included combinations
with metformin,37–40 with metformin plus a sulfonylurea,37
and with pioglitazone or pioglitazone plus metformin.40
When EMPA 10 mg or 25 mg were added to multidose
insulin with or without metformin, there was a statistically
significant reduction in body weight but a nonsignificant
reduction in SBP.41 In combination with metformin, EMPA
25 mg resulted in statistically significant reductions in body
weight and SBP compared with glimepiride.39
EMPA in combination studies resulted in small
increases in low-density lipoprotein cholesterol (LDL-C)
and high-density lipoprotein cholesterol (HDL-C). When
EMPA was added to metformin plus pioglitazone, there

5798
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were small increases in HDL-C in placebo-controlled
studies: 0.06 mmol/L (2.32 mg/dL) with EMPA 10 mg
and 0.03 mmol/L (1.16 mg/dL) with EMPA 25 mg.37 With
metformin only, increases in HDL-C of 0.08 mmol/L
(3.09 mg/dL) and 0.06 mmol/L (2.32 mg/dL) with EMPA
10 and 25 mg, respectively, were seen relative to placebo.36
EMPA as an add-on to metformin has been reported to
result in small increases in LDL-C (adjusted mean increase
0.15 mmol/L).40 Finally, Phase III studies with EMPA have
shown reductions in plasma uric acid.33,35,37 This may be
clinically important in that hyperuricemia has been identified
as an independent risk factor for cardiovascular disease.42
EMPA was also studied in people with moderate renal
insufficiency. EMPA 25 mg resulted in an adjusted mean
placebo subtracted A1c change of −0.42% at week 24 in
patients with estimated glomerular filtration rate (eGFR) 30
to 60 mL/min/1.73 m2.43 In patients with stage 2 and 3
chronic kidney disease, EMPA resulted in significant reductions of A1c, body weight, and SBP compared with placebo
after 52 weeks.43
Results from these EMPA studies are consistent with
results seen from other agents within the class. A systematic
review and meta-analysis of clinical trials comparing an
SGLT2 inhibitor with placebo (45 studies, n=11,232) or an
active comparator (13 studies, n=5,175) reported improved
glycemic control, reduced body weight, and reduced blood
pressure with SGLT2 inhibitor therapy.44

Safety of empagliflozin
The most frequently occurring adverse events with EMPA are
urinary tract infections (7.6% with placebo vs 9.3% and 7.6%
with EMPA 10 and 25 mg, respectively) and genital mycotic
infections (in female patients: 1.5% with placebo vs 5.4%
and 6.4% with EMPA 10 and 25 mg, respectively).23 Adverse
events related to osmotic diuresis and volume contraction

Drug Design, Development and Therapy 2015:9
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Table 3 Efficacy and safety of EMPA in randomized, double-blind Phase III trials of patients with type 2 diabetes mellitus
Study

Regimen and duration

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 98.142.124.110 on 07-Sep-2016
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Monotherapy
Roden et al35

EMPA 10 mg (n=224)
EMPA 25 mg (n=87)
PBO (n=228)
24 weeks
Combination therapy
Häring et al37
MET + SU + one of:
EMPA 10 mg (n=225)
EMPA 25 mg (n=216)
PBO (n=225)
24 weeks
Häring et al38
MET + one of:
EMPA 10 mg (n=217)
EMPA 25 mg (n=213)
PBO (n=207)
24 weeks
Ridderstråle et al39 MET + one of:
EMPA 25 mg (n=765)
GLIM 1–4 mg (n=780)
104 weeks
Kovacs et al40
PIO ± MET + one of:
EMPA 10 mg (n=165)
EMPA 25 mg (n=168)
PBO (n=165)
24 weeks

Efficacy

Safety

A1c (%)

Body
SBP
weight (kg) (mmHg)

UTIs (%) Events consistent Events consistent
with GMIs (%)
with UTIs (%)

−0.66
−0.78
0.08

−2.26
−2.48
−0.33

−2.9
−3.7
−0.3

6
4
4

3 M, 4 F
1 M, 9 F
0 M, 0 F

2 M, 15 F
1 M, 13 F
2 M, 9 F

−0.82
−0.77
−0.17

−2.16
−2.39
−0.39

−4.1
−3.5
−1.4

9.4
6.9
6.7

0.9 M, 4.5 F
0.9 M, 3.9 F
0.9 M, 0.9 F

2.7 M, 18.0 F
0 M, 17.5 F
2.7 M, 13.3 F

−0.70
−0.77
−0.13

−2.08
−2.46
−0.45

−4.5
−5.2
−0.4

5.1
5.6
4.9

0.8 M, 7.6 F
0.8 M, 9.7 F
0 M, 0 F

0 M, 12.0 F
0.8 M, 11.8 F
2.6 M, 7.7 F

−0.66
−0.55

−3.1
1.3

−3.1
2.5

14
13

9 M, 15 F
1 M, 3 F

7 M, 22 F
5 M, 23 F

−0.59
−0.72
−0.11

−1.62
−1.47
0.34

−3.14
−4.00
0.72

1
4.5
10.7
10.9

7.2 M, 9.8 F
1.2 M, 6.0 F
1.4 M, 3.3 F

3.6 M, 30.5 F
2.4 M, 21.7 F
8.2 M, 22.8 F

Note: Adapted with permission from Miller E, Shubrook JH. Role of the kidneys and sodium glucose co-transporter 2 (sglt2) inhibitors in the treatment of type 2 diabetes
mellitus. Osteopathic Family Physician. 2015;1(5):10–30.58 Copyright © 2015.
Abbreviations: EMPA, empagliflozin; F, female; GLIM, glimepiride; GMI, genital mycotic infections; M, male; MET, metformin; PBO, placebo; PIO, pioglitazone; SBP, systolic
blood pressure; SU, sulfonylurea; UTI, urinary tract infection.

have been evaluated from pooled data from Phase I, II,
and III studies in 11,000 patients.45 In that analysis, the
overall incidence of volume depletion events was 1.4% with
EMPA 10 mg and 1.5% with EMPA 25 mg vs 1.4% with
placebo. The incidence of these events was higher in subjects
aged 75 years, those with eGFR 30 mL/min/1.73 m2,
and those also receiving diuretic therapy.21
Increased rates of hypoglycemia were not seen in EMPA
monotherapy or in combination with insulin sensitizers. However, when combined with other medications that have a high
risk of hypoglycemia (sulfonylureas or insulin), the EMPA
arms of these studies had higher rates of hypoglycemia.38,40,41

Recent updates
Empagliflozin and glucagon
Ferrannini et al34 demonstrated that those people with type
2 diabetes who took an SGLT2 inhibitor had an increase in
glucagon and hepatic glucose production. This has a potential
explanation (that Bonner et al46 recently published) in that
there is SGLT2 expression in the α-cells in the pancreas.

Drug Design, Development and Therapy 2015:9

This will need further investigation. Clinically, it may be
important to pair SGLT2 inhibitors that counteract this
increase in glucagon such as dipepitdyl-peptidase -4 inhibitor (DPP-4) inhibitors or glucaogon like peptide 1 receptor
agonist (GLP-1 RA).

Empagliflozin/linagliptin-fixed dose
combination
Empagliflozin has been recently approved (February 2015)
in a combination therapy with linagliptin (LINA) (a DPP-4
inhibitor). 47 This medication, under the brand name
Glyxambi® (Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, CT, USA), is available as 10 mg EMPA/5 mg of
LINA or 25 mg empagliflozin/5 mg of LINA.44 Boehringer
Ingelheim manufactures both EMPA and LINA.
In a study, EMPA 25/LINA 5 mg (n=134) and EMPA/
LINA 10 mg/5 mg (n=135) were utilized in drug-naïve
type 2 diabetes with a baseline HbA1c of 7.99% and 8.04%,
respectively. HbA1c improved by 1.08% (EMPA/LINA
25 mg/5 mg) and 1.24% (EMPA/LINA 10 mg/5 mg) and
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body weight reductions of 2.0 and 2.7 kg were seen.48
More people achieved an HbA1c of less than 7% at 24 and
52 weeks in the combination therapy than the individual
medications.48
This study group also completed a trial with fixed-dose
EMPA/LINA as add-on to metformin. In this 52 week trial,
subjects were randomized to EMPA/LINA 25 mg/5 mg
(n=137), EMPA/LINA 10 mg/5 mg (n=136), or the individual
medications, EMPA 25 (n=141), EMPA 10 mg (n=140), or
LINA 5 mg (n=132). The fixed combinations had greater
A1c reductions despite slightly lower starting A1cs. EMPA/
LINA 25 mg/5 mg reduced A1c by 1.19%, and EMPA/LINA
10 mg/5 mg reduced A1c by 1.08%. The single agents reduced
A1c 0.63%, 0.66%, and 0.7%, respectively. Weight loss was
similar in the fixed combination groups and single agent
EMPA. The 24-week weight loss was 3.0 kg in EMPA/LINA
25 mg/5 mg, 2.6 kg in EMPA/LINA 10 mg/5 mg, 3.2 kg
in EMPA 25 mg, 2.5 kg in EMPA 10 mg, and 0.7 kg in
LINA 5 mg.49
Hypoglycemic risk and adverse reactions, such as urinary
tract infections, pancreatitis, and cholesterol changes were
monitored in the aforementioned trials.48,49 Results demonstrated that there was no increase in severe hypoglycemia
even with the fixed dose combination. There was no increase
or change in adverse reactions when these two medications
were administered simultaneously vs their individual adverse
reaction profiles.48,49

Empagliflozin and renal indices
When the SGLT2 inhibitors were first released, there was
some clinical concern that permissive glucosuria would
contribute to advancing nephropathy despite some reassurance from the experience of people with familial renal
glucosuria. In early clinical studies, there is some evidence
that the contrary may be true. In a series of studies, patients
with type 2 diabetes with preexisting microalbuminuria were
randomized to EMPA 10, 25 mg, or placebo. Those on EMPA
had reported decreased urinary albumin to creatinine ratio
by 30% and 25%, respectively, compared to placebo.50 This
suggests that despite permissive hyperglycemia, there may
be some renoprotection from this class of medications. This
is still exploratory and would need to be repeated.
Another study51 explored the effect of EMPA on the intraglomerular hemodynamic profile and hyperfiltration in patients
with type 1 diabetes. In this study,52 27 patients who had hyperfiltration but no hypertension or albuminuria, and 13 who had a
normal GFR (and no hypertension/albuminuria) were given 8
weeks of EMPA 25 mg daily. The investigators found that there
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was an increase in renal afferent resistance in the hyperfiltrators with a reduction in glomerular hydrostatic pressure, but no
change in renal efferent resistance. These parameters were not
affected by EMPA in the normal GFR controls. This provides
some evidence that EMPA could have some renoprotective
effects and should be investigated further.52

Empagliflozin in type 1 diabetes
Empagliflozin may play a role in the treatment of type 1
diabetes. A recent expert opinion paper summarized the
potential use of SGLT2 inhibitors in patients with type 1
diabetes.53 Early studies have shown that use of SGLT2
inhibitors in type 1 diabetes can reduce HbA1c in 8 weeks
by 0.4% in those with a baseline of 8.0%. Further, there
was a statistical reduction in symptomatic hypoglycemia
and total insulin dose. Mean urinary glucose excretion
increased from 19 g/24 h to 134 g/24 h. Weight decreased
by 2.7 kg, and there was also a reduction in waist circumference of 3.8 cm. There were two reported cases of diabetic
ketoacidosis, but they were associated with a pump failure
and an episode of gastroenteritis.51 This appears to be a
significant finding that may be related to normoglycemia
and relative insulinopenia. This is currently under further
investigation.
Recently, it was shown that SGLT2 inhibition attenuated renal hyperfiltration in subjects with type 1 diabetes
by affecting tubular glomerular feedback mechanisms and,
potentially, by its effects on nitric oxide.54,55 Further study
is needed to determine the safety and long-term efficacy of
this medication in type 1 diabetes mellitus.

Clinical summary of EMPA
The SGLT2 inhibitors are a welcome addition to the diabetes treatment armamentarium. EMPA addresses hyperglycemia from a noninsulin centric manner, which can be
complementary to other agents and can be used even in
those who no longer make insulin. Further, EMPA appears
to have significant nonglycemic benefits including weight
loss, reduction in blood pressure, and reduction in uric acid.
This is balanced by minor changes in lipid parameters and
an increase in urinary tract and genital mycotic infections.
While it was suspected by some physicians (including
the authors of this paper) that glucosuria would result in
adverse renal consequences, early studies actually support
renal benefit from SGLT2 inhibitors from reduced renal
hyperperfusion and reduction in protein excretion. With
this profile EMPA and the other SGLT2 inhibitors are
significant additions to the market for diabetes treatment.
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This is reflected by inclusion of this class of medications
in the 2015 American Association of Clinical Endocrinologists treatment guidelines.56 While the role of these agents
in type 1 diabetes is unclear, anecdotal reports suggest that
when used carefully these agents have a significant clinical
benefit in type 1 diabetes.

Conclusion
Empagliflozin (along with the other SGLT2 inhibitors) is a
novel addition to treatment of type 2 diabetes. Empagliflozin
has glycemic and nonglycemic benefits. Glycemic benefits
are obvious with evidence based on lowering an HbA1c in
an insulin-independent mechanism. Nonglycemic benefits
include weight loss, blood pressure lowering, and decreased
urinary protein excretion.
Diabetes is a progressive disorder, and combination
therapy is expected as the disease progresses. Reducing
the medication burden can help to improve adherence to
complicated medication regimens. Glyxambi® is a novel
combination therapy option that includes new treatment
pathways that do not rely on intact insulin secretion. Current
guidelines recommend combination therapy early in type 2
diabetes therapy to address the variety of pathophysiologic
mechanisms.51 Conversely, the cost of these agents may be
prohibitive for some patients. Depending on drug coverage and generic availability, cost should be considered as
increased cost could cause decreased adherence and disease
management.
SGLT2 inhibitors may be seen in T2DM patients who
have failed to reach HbA1c goals with single drug therapy
with metformin and life style changes. The use of SGLT2
inhibitors can be explored in patients who may need assistance with weight loss and potential improvement in blood
pressure. They may be tried as an initial add-on to metformin
or, in weight loss, or may be used after failure of a GLP-1.
These should not be used in patients with renal failure, those
at increased risk of candidiasis infections, or those at risk
for hypotension.
In the future, SGLT2 inhibitors may be found in additional combination products. They may be found useful in
patients with type 1 diabetes. Further studies are needed to
explore further benefits or risks with SGLT2 inhibitors.
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